Compare LAES & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAES | TBPH |
|---|---|---|
| Founded | 2022 | 2013 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 606.5M | 824.9M |
| IPO Year | 2022 | 2013 |
| Metric | LAES | TBPH |
|---|---|---|
| Price | $2.80 | $16.60 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | $4.00 | ★ $18.40 |
| AVG Volume (30 Days) | ★ 12.2M | 342.9K |
| Earning Date | 03-31-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 279.13 |
| EPS | N/A | ★ 2.06 |
| Revenue | N/A | ★ $15,386,000.00 |
| Revenue This Year | $93.36 | $8.46 |
| Revenue Next Year | $43.06 | N/A |
| P/E Ratio | ★ N/A | $8.13 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.99 | $8.33 |
| 52 Week High | $8.71 | $21.03 |
| Indicator | LAES | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 49.63 | 57.17 |
| Support Level | $2.54 | $16.14 |
| Resistance Level | $2.88 | $17.24 |
| Average True Range (ATR) | 0.23 | 0.41 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 55.71 | 60.18 |
SEALSQ Corp develops certified secure microcontrollers and implements post-quantum cryptography. The company develops solutions including post-quantum microchips and devices that can be used in a variety of applications, from multi-factor authentication, home automation, and IT network infrastructure to automotive, industrial automation, and control systems. The company's vaultIC range offers a set of ready-to-use secure elements designed to implement embedded security for any kind of device with fast time-to-market and high flexibility. The company's products include VaultIC155, VaultIV18x, VaultIC292, and VaultIC40x. The company generates a majority of its revenue from North America, while it also has its presence in Europe, Middle East & Africa, Asia Pacific, and Latin America.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.